Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000172

Drug Information
NameMS-275
SynonymsNCI60_038022; Entinostat, SNDX-275, MS-27-275, MS-275; CID4261; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; Entinostat; Entinostat (USAN/INN); MolPort-005-942-713; AC1L1HRM; CHEMBL27759; EC-000.2117; pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NCGC00165833-01; NSC-706995; nchembio.275-comp4; ZINC01488870; S1053_Selleck; AC1Q5NOI; SNDX 275; IN1470; NSC706995; LS-185285; MS-27-275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; 209783-80-2; Histone Deacetylase Inhibitor I; NCGC00165833-02; MS 275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; SNDX-275; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; MS 27-275; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; ms-275; AR-1L2666; nchembio.313-comp19; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; C118739; D09338; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester
CompanySchering AG
IndicationMelanoma, Prostate, Lung and Colorectal Cancer
[ICD9: 140-229, 153, 154, 172   ICD10: C00-C96, C18-C21, C43]
Phase II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-
24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,2
5,26)
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N
Canonical SMILESC1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 209783-80-2
PubChem Compound IDCID 4261.
PubChem Substance IDSID 529250.
ClinicalTrials.govNCT00828854;
TargetHistone deacetylaseInhibitor[1][2][3][4]
Ref 1Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol Cancer Ther. 2009 May 5. [Epub ahead of print] To Reference
Ref 2Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol. 2009;257(1-2):97-104. Epub 2009 Apr 8. To Reference
Ref 3Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. To Reference
Ref 4Cell Res. 2007 Mar;17(3):195-211.HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543